BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Mick Stanley

Session 3  – International Collaboration Strategy

Date:27 July (Wednesday)
Time:  12:20 – 13:50 (GMT+8)

Mick Stanley

General Manager
​GlaxoSmithKline Taiwan

As general manager of GSK Taiwan, Mick brings 20 years of global leadership experience in vaccines, biopharma marketing and sales. 

Mick has focused much of his two decades in the pharmaceutical industry on the development of vaccines. Prior to joining GSK Taiwan, Mick was in Belgium as the Vaccines Commercialization Lead covering 13 of GSK’s top vaccine products, accumulating £1.3 billion of annual sales. 

Mick is passionate about applying his love of business to making impact on public health and preventing diseases. In the US, while he led in-line marketing and sales teams and served as the commercial lead for Human & Health Services, he worked closely with the US government during the 2009 Flu pandemic, giving him unique insight into building successful public-private partnerships. 

Mick relocated with his wife and two kids from Belgium to Taiwan since 2020. He and his family are fully enjoying life in Taipei and the people of Taiwan.

Speech title & Synopsis

Clinical Trial Ecosystem

Clinical trial is the crucial link from laboratory to market in pharmaceutical R&D. Local clinical trials create an ecosystem that builds upon foreign investment, experienced physicians and researchers, and good regulatory framework. In Taiwan, the advantages of comprehensive public health database, speedy and excellent medical services, as well as sound legal environment with strong IP protection and compliance with international standards have attracted global pharmaceutical companies to conduct clinical trials locally. This presentation looks into the success of Taiwan’s ecosystem and also points to future development opportunities to position Taiwan as the Asian hub for clinical trial R&D.